US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
31.20
-1.00 (-3.11%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
Next >
Arcutis Biotherapeutics (NASDAQ:ARQT) Clears All Eight Growth Rules as Fundamentals Accelerate
↗
October 22, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Looks Undervalued as Growth and Margins Support the Value Case
↗
October 20, 2026
Via
Chartmill
2 Stocks That Could Soar in Q4
↗
October 12, 2026
These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth from realizing value in their pipelines.
Via
The Motley Fool
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth and Improving Fundamentals
↗
October 01, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): Affordable Growth With Strong Upside Potential
↗
September 21, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): Strong Growth Meets a High-Quality Technical Setup
↗
September 19, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals
↗
September 07, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum
↗
August 24, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup
↗
August 19, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals
↗
August 14, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup
↗
August 11, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Jumps on Q2 Beat and Raised Guidance
↗
August 05, 2026
Via
Chartmill
Arcutis (ARQT) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
ZORYVE franchise revenue surged 59% year-over-year, driving profitability.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
↗
August 06, 2026
Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.
Via
The Motley Fool
Topics
Regulatory Compliance
Arcutis Biotherapeutics Q2 Earnings Call Highlights
↗
August 05, 2026
Arcutis Biotherapeutics (NASDAQ:ARQT) reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical...
Via
MarketBeat
Topics
Earnings
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup
↗
July 23, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum
↗
July 20, 2026
Via
Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup
↗
July 17, 2026
Via
Chartmill
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
↗
July 03, 2026
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
Via
The Motley Fool
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%
↗
June 23, 2026
Via
The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price
↗
June 22, 2026
Via
Chartmill
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
↗
June 09, 2026
Arcutis Biotherapeutics (NASDAQ:ARQT) executives said ZORYVE continues to post strong growth and outlined several regulatory and clinical catalysts expected over the next year, while emphasizing that...
Via
MarketBeat
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
↗
June 03, 2026
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide
↗
May 06, 2026
Via
Chartmill
Arcutis (ARQT) Q1 2026 Earnings Transcript
↗
May 07, 2026
Arcutis (ARQT) Q1 2026 Earnings Transcript
Via
The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate
↗
April 14, 2026
Arcutis Biotherapeutics (ARQT) combines strong earnings growth with a bullish technical setup, presenting a potential breakout opportunity for momentum investors.
Via
Chartmill
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
↗
April 08, 2026
Focused on innovative dermatology treatments, this biopharma firm reported a notable insider sale amid a strong year for its shares.
Via
The Motley Fool
Topics
Regulatory Compliance
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Surpasses Q4 Estimates and Raises 2026 Sales Outlook
↗
February 25, 2026
Via
Chartmill
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows Technical Breakout Setup
↗
February 13, 2026
Via
Chartmill
Arcutis (ARQT) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Arcutis (ARQT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
Next >
